Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 20, 2026, 2:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 230 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Ketamine + Placebo Clear all
Withdrawn Phase 4 Interventional

Ketamine vs. Placebo as Adjunctive Therapies for Severe Alcohol Withdrawal

NCT02823977
View directory record Official record
Conditions
Alcohol Withdrawal
Interventions
Ketamine, Dexmedetomidine, Normal saline
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 18, 2018 · Synced Sep 20, 2026, 2:38 AM EDT
Completed Phase 2 Interventional Results available

Ketamine for the Treatment of Opioid Use Disorder and Depression

NCT04177706
View directory record Official record
Conditions
Depression, Opioid-use Disorder, Opioid Abuse
Interventions
Ketamine Hydrochloride, Placebo
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced Sep 20, 2026, 2:38 AM EDT
Completed Phase 2 Interventional Results available

A Study of CLE-100 (Oral Esketamine) in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO Study

NCT04103892
View directory record Official record
Conditions
Adjunctive Treatment of Major Depressive Disorder
Interventions
CLE-100, placebo
Drug
Lead sponsor
Clexio Biosciences Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
45
States / cities
Bentonville, Arkansas • Little Rock, Arkansas • Anaheim, California + 39 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Sep 20, 2026, 2:38 AM EDT
Terminated Not applicable Interventional Results available

Lidocaine and Ketamine in Abdominal Surgery

NCT00721110
View directory record Official record
Conditions
Abdominal Hysterectomy (& Wertheim)
Interventions
Lidocaine, Placebo, Ketamine, Ketamine + Lidocaine
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Mayfield Heights, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 25, 2017 · Synced Sep 20, 2026, 2:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pilot Study of ORG 25935 Modulation of Ketamine-induced Behavioral and Cognitive Effects in Healthy Male Subjects

NCT00700076
View directory record Official record
Conditions
Healthy
Interventions
Ketamine and Org 25935, Placebo and Ketamine
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years · Male only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Sep 20, 2026, 2:38 AM EDT
Completed Early Phase 1 Interventional

Ketamine for MS Fatigue

NCT06064162
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
ketamine
Drug
Lead sponsor
Alta Bates Summit Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated Jun 7, 2025 · Synced Sep 20, 2026, 2:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Crossover Study to Evaluate the Abuse Potential of Intranasal Esketamine Compared to Racemic Intravenous Ketamine in Nondependent, Recreational Drug Users

NCT02682225
View directory record Official record
Conditions
Drug Abuse
Interventions
Intravenous placebo, Intranasal placebo, Intravenous racemic ketamine, Esketamine 112 mg, Esketamine 84 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 26, 2025 · Synced Sep 20, 2026, 2:38 AM EDT
Terminated Phase 2 Interventional Results available

Ketamine in Chronic Kid's (KiCK) Pain

NCT01755169
View directory record Official record
Conditions
Chronic Pain
Interventions
Ketamine, Placebo
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
8 Years to 20 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 22, 2017 · Synced Sep 20, 2026, 2:38 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Ketamine for Acute Migraine in the Emergency Department

NCT02697071
View directory record Official record
Conditions
Headache
Interventions
Ketamine, Normal Saline
Drug
Lead sponsor
Carilion Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Roanoke, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 25, 2021 · Synced Sep 20, 2026, 2:38 AM EDT
Terminated Phase 4 Interventional Results available

Ketamine-assisted Therapy for Advanced GI Cancer

NCT06077487
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma, Pain, Acute, Gastrointestinal Cancers, Demoralization
Interventions
Ketamine, Ketamine Injectable Product, Meaning and Purpose therapy, Placebo, Questionnaires
Drug · Behavioral · Other
Lead sponsor
Brian Anderson, MD
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 20, 2025 · Synced Sep 20, 2026, 2:38 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Analgesics in the Pre-hospital Setting: Implications on Hemorrhage Tolerance - Ketamine

NCT03621085
View directory record Official record
Conditions
Hemorrhage, Healthy
Interventions
Ketamine Hydrochloride, Placebo
Drug · Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 45 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 25, 2021 · Synced Sep 20, 2026, 2:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assessment of Effect of Rapastinel on Driving Performance

NCT03814733
View directory record Official record
Conditions
Driving Performance
Interventions
Rapastinel, Alprazolam, Ketamine, Rapastinel Matched Placebo, Alprazolam Matched Placebo, Ketamine Matched Placebo
Drug
Lead sponsor
Naurex, Inc, an affiliate of Allergan plc
Industry
Eligibility
21 Years to 65 Years
Enrollment
107 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
San Clemente, California
Source: ClinicalTrials.gov public record
Updated Jul 10, 2019 · Synced Sep 20, 2026, 2:38 AM EDT
Terminated Phase 4 Interventional Results available

Effect of Ketamine on Postoperative Clinical Outcomes

NCT01365195
View directory record Official record
Conditions
Colorectal Surgery
Interventions
Placebo, Ketamine high-dose, Ketamine low-dose
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 1, 2022 · Synced Sep 20, 2026, 2:38 AM EDT
Terminated Phase 3 Interventional

Preventing pAIn With NMDA Antagonists - Steroids in Thoracoscopic lObectomy Procedures (PAIN-STOP) Pilot Trial

NCT02950233
View directory record Official record
Conditions
Pain, Postoperative
Interventions
NMDA active, Steroid active, NMDA placebo, Steroid placebo
Drug
Lead sponsor
Population Health Research Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 17, 2020 · Synced Sep 20, 2026, 2:38 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

NCT02418585
View directory record Official record
Conditions
Treatment-resistant Depression
Interventions
Esketamine, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
10
States / cities
Birmingham, Alabama • Orange, California • San Rafael, California + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Sep 20, 2026, 2:38 AM EDT
Terminated Phase 2 Interventional Results available

Perioperative Ketamine in Opioid-Tolerant Patients Undergoing Lumbar Spine Surgery

NCT04220489
View directory record Official record
Conditions
Opioid Dependence, Chronic Pain
Interventions
Ketamine, Placebo Comparator
Drug
Lead sponsor
Jacques E. Chelly
Other
Eligibility
18 Years to 70 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 29, 2024 · Synced Sep 20, 2026, 2:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

GABA-glutamate Interactions and Psychosis

NCT00611572
View directory record Official record
Conditions
Cognitive Dysfunction
Interventions
iomazenil
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 45 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2018
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced Sep 20, 2026, 2:38 AM EDT
Withdrawn Phase 2 Interventional

Ketamine and Midazolam Infusions for CRPS: Feasibility Study

NCT05945147
View directory record Official record
Conditions
Complex Regional Pain Syndromes
Interventions
Ketamine, Midazolam, Normal Saline
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2099
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Sep 20, 2026, 2:38 AM EDT
Completed Not applicable Interventional Results available

Intranasal Ketamine in Treatment-Resistant Depression

NCT01304147
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Ketamine, placebo
Drug
Lead sponsor
James Murrough
Other
Eligibility
21 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 7, 2017 · Synced Sep 20, 2026, 2:38 AM EDT
Recruiting Phase 1Phase 2 Interventional

Pilot Study of RR-HNK in OCD

NCT06575075
View directory record Official record
Conditions
Obsessive-Compulsive Disorder
Interventions
RR-HNK/Hydroxynorketamine, Placebo
Drug
Lead sponsor
Carolyn Rodriguez
Other
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 20, 2026, 2:38 AM EDT
Completed Phase 4 Interventional Results available

Efficacy of Ketamine for Improvement in Postoperative Pain Control After Spinal Fusion for Idiopathic Scoliosis

NCT02651324
View directory record Official record
Conditions
Idiopathic Scoliosis, Post-operative Pain
Interventions
Ketamine, Placebo
Drug · Other
Lead sponsor
Albany Medical College
Other
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Feb 19, 2025 · Synced Sep 20, 2026, 2:38 AM EDT
Completed Phase 1 Interventional

Double-Blind Trial of Ketamine Therapy Plus or Minus Naltrexone in Treatment Resistant Depression (TRD)

NCT02911597
View directory record Official record
Conditions
Depression
Interventions
Naltrexone
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 23, 2018 · Synced Sep 20, 2026, 2:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Examine The Effects Of PF-04958242 On Ketamine-Induced Cognitive Impairment In Healthy Volunteers

NCT01749098
View directory record Official record
Conditions
Schizophrenia
Interventions
PF-04958242, Ketamine, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
21 Years to 45 Years · Male only
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
2
States / cities
New Haven, Connecticut • West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 20, 2019 · Synced Sep 20, 2026, 2:38 AM EDT